The industry awaits a number of readouts and approvals for drugs that address market gaps and enrich treatment landscapes with huge sales potential to boot.
The past two years were all about COVID-19 vaccines and therapeutics. Now, imminent approvals in oncology, hematology and autoimmune disorders are set to enhance patient convenience.